drugset / Trial / NCT04760730
Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19)
RandomizedParallel-groupSingle-blindPrevention
Summary
This is a Phase I/II, parallel group, single blinded (participant blinded), randomised study assessing the immunogenicity and safety of AZD1222 and rAd26-S administered as heterologous prime-boost in alternating order in 2 study groups for the Prevention of COVID-19.
Timeline
- Start
- 2021-07-13
- Primary completion
- 2022-03-29
- Completion
- 2022-07-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD1222 | Vaccine | 5e+10 unknown | Intramuscular |
| Subject | rAd26-S | Vaccine | 1e+11 unknown | Intramuscular |